Positive Prospects for Inventiva: Pivotal NATiV3 Trial Progress, Anticipated LEGEND Study Results, and Expansion into Asian Markets
In a report released today, Ed Arce from H.C. Wainwright maintained Inventiva (IVA – Research Report) to a Buy, with a price target of $36...
Source: businessinsider.com